ProRx Pharma has announced the addition of six injectable products to its portfolio, aimed at supporting the growing demand ...

For the fiscal year 2025, Hikma has reiterated its guidance, expecting group revenue to grow between 4% and 6%, with core operating profit projected to be in the range of $730 million to $770 million.

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

ProRx Pharma, the leading health and wellness 503B outsourcing facility, today announced the addition of six new injectable products designed to support the rising demand for preventive care: ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

More specifically, a 2024 study published in JAMA Network Open found a 45 percent higher risk of suicidal thoughts in people ...

If you are taking a weight loss medication such as Ozempic, Wegovy, or Zepbound for obesity or other health concerns, you may ...